Inclusion Criteria:

          -  Adult subjects; age ≥ 18 years

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

          -  Subjects diagnosed with advanced solid tumors.

          -  For Part 1 and Part 2 (IPH5201 in monotherapy or combined with durvalumab):Subjects
             must be refractory to standard therapy or for which no standard therapy exists.

          -  For Part 3 (IPH5201 combined with durvalumab and oleclumab): Subjects must have
             received and radiologically progressed on 1 prior line of systemic therapy for
             metastatic pancreatic ductal adenocarcinoma.

          -  Subjects must have at least 1 measurable lesion according to RECIST v1.1.

          -  Subjects must provide tumor specimens .

        Exclusion Criteria:

          -  Receipt of any conventional or investigational anticancer therapy (anti-CTLA-4,
             anti-PD-1, anti-PD-L1 antibodies) within 21 days of the planned first dose.

          -  Receipt of agents targeting CD73, CD39, or adenosine receptors.

          -  Concurrent enrollment in another therapeutic clinical study.

          -  Any toxicity (excluding alopecia) from prior standard therapy that has not been
             completely resolved to baseline at the time of consent.

               -  No toxicity leading to permanent discontinuation of prior IO therapy

               -  Subjects must not have required the use of additional immunosuppression other
                  than corticosteroids

          -  Active or prior documented autoimmune or inflammatory disorders within the past 5
             years

          -  Cardiac and vascular criteria:

               -  Presence of myocardial infarction or unstable angina , or stroke, within 6
                  months.

               -  Congestive heart failure, serious cardiac arrhythmia requiring medication, or
                  uncontrolled hypertension

               -  History of severe hypertension

               -  History of any grade of blood clot within 6 months

          -  Active infection, including tuberculosis; hepatitis B virus (HBV); hepatitis C virus
             (HCV); or human immunodeficiency virus (HIV)

          -  Uncontrolled illness including certain lung diseases, uncontrolled diabetes, serious
             chronic gastrointestinal conditions associated with diarrhea, or psychiatric
             illness/social situations that would limit compliance with study.

          -  Other invasive malignancy within 2 years.

          -  Major surgery within 28 days prior to first dose

          -  Female subjects who are pregnant or breast feeding